As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.
Recent LYEL News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/15/2026 04:15:12 AM
- Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/03/2026 08:23:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:26:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 11:24:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:50:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:12:21 PM
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results • GlobeNewswire Inc. • 03/12/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:05:17 PM
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 01:46:32 AM
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma • GlobeNewswire Inc. • 02/12/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:05:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:00:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 01:58:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:02:57 PM
- Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge • GlobeNewswire Inc. • 12/24/2025 11:00:00 AM
- Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 • PR Newswire (Canada) • 12/19/2025 12:44:00 PM
- Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 • PR Newswire (US) • 12/19/2025 12:44:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/18/2025 09:05:29 PM
- Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results • IH Market News • 12/08/2025 03:24:15 PM
